Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size

Yong Kang Lee, Kyu Sik Jung, doyoung kim, Jin Young Choi, Beom Kyung Kim, Seungup Kim, Junyong Park, SangHoon Ahn, KwangHyub Han, Gyoung Min Kim, ManDeuk Kim, Sung Il Park, Jong Yun Won, Do Yun Lee

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background and Aim: This study aims to evaluate clinical outcomes of patients with hepatocellular carcinoma who underwent transarterial chemoembolization (TACE) using drug-eluting beads (DEB). Patients and Methods: This study retrospectively compared the clinical outcomes of 250 consecutive patients who underwent DEB-TACE (n = 106) or conventional TACE (cTACE) (n = 144) in a tertiary center between January 2010 and April 2014. The median age of the patients was 62 years and 81.6% were men. The primary endpoint was overall survival (OS). The time to progression (TTP), radiological response rate using modified response evaluation criteria in solid tumors criteria at 1 month after treatment, and complication rates within 1 month were also compared. Results: The most common etiology was hepatitis B virus infection. The median index tumor size was 2.8 cm, and 150 (60.0%) patients had Barcelona Clinic Liver Cancer stage B. Median TTP in the cTACE group was longer than in the DEB-TACE group (13.3 vs10.8 months; P = 0.023). However, DEB-TACE and cTACE groups showed no significant differences for mean OS (46.6 vs 44.9 months; P = 0.660) and disease control rate at 1 month (78.3% vs 86.8%; P = 0.076). The OS, TTP, and disease control rate were also not different between two groups, even when subgrouped by index tumor size. The complication rates within 1 month were higher in the cTACE group (6.6% vs 14.6%; P = 0.048). Conclusions: Drug-eluting beads TACE appears to be a safe intra-arterial therapy. However, it is not superior to cTACE in terms of efficacy. Tumor size might not be a criterion to select treatment modality between cTACE and DEB-TACE in terms of efficacy.

Original languageEnglish
Pages (from-to)487-496
Number of pages10
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume32
Issue number2
DOIs
Publication statusPublished - 2017 Feb 1

Fingerprint

Hepatocellular Carcinoma
Pharmaceutical Preparations
Neoplasms
Survival
Virus Diseases
Liver Neoplasms
Hepatitis B virus
Disease Progression
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{df271ec110954e488f69b22a8cad9572,
title = "Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size",
abstract = "Background and Aim: This study aims to evaluate clinical outcomes of patients with hepatocellular carcinoma who underwent transarterial chemoembolization (TACE) using drug-eluting beads (DEB). Patients and Methods: This study retrospectively compared the clinical outcomes of 250 consecutive patients who underwent DEB-TACE (n = 106) or conventional TACE (cTACE) (n = 144) in a tertiary center between January 2010 and April 2014. The median age of the patients was 62 years and 81.6{\%} were men. The primary endpoint was overall survival (OS). The time to progression (TTP), radiological response rate using modified response evaluation criteria in solid tumors criteria at 1 month after treatment, and complication rates within 1 month were also compared. Results: The most common etiology was hepatitis B virus infection. The median index tumor size was 2.8 cm, and 150 (60.0{\%}) patients had Barcelona Clinic Liver Cancer stage B. Median TTP in the cTACE group was longer than in the DEB-TACE group (13.3 vs10.8 months; P = 0.023). However, DEB-TACE and cTACE groups showed no significant differences for mean OS (46.6 vs 44.9 months; P = 0.660) and disease control rate at 1 month (78.3{\%} vs 86.8{\%}; P = 0.076). The OS, TTP, and disease control rate were also not different between two groups, even when subgrouped by index tumor size. The complication rates within 1 month were higher in the cTACE group (6.6{\%} vs 14.6{\%}; P = 0.048). Conclusions: Drug-eluting beads TACE appears to be a safe intra-arterial therapy. However, it is not superior to cTACE in terms of efficacy. Tumor size might not be a criterion to select treatment modality between cTACE and DEB-TACE in terms of efficacy.",
author = "Lee, {Yong Kang} and Jung, {Kyu Sik} and doyoung kim and Choi, {Jin Young} and Kim, {Beom Kyung} and Seungup Kim and Junyong Park and SangHoon Ahn and KwangHyub Han and Kim, {Gyoung Min} and ManDeuk Kim and Park, {Sung Il} and Won, {Jong Yun} and Lee, {Do Yun}",
year = "2017",
month = "2",
day = "1",
doi = "10.1111/jgh.13501",
language = "English",
volume = "32",
pages = "487--496",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "2",

}

Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma : Emphasis on the impact of tumor size. / Lee, Yong Kang; Jung, Kyu Sik; kim, doyoung; Choi, Jin Young; Kim, Beom Kyung; Kim, Seungup; Park, Junyong; Ahn, SangHoon; Han, KwangHyub; Kim, Gyoung Min; Kim, ManDeuk; Park, Sung Il; Won, Jong Yun; Lee, Do Yun.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 32, No. 2, 01.02.2017, p. 487-496.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma

T2 - Emphasis on the impact of tumor size

AU - Lee, Yong Kang

AU - Jung, Kyu Sik

AU - kim, doyoung

AU - Choi, Jin Young

AU - Kim, Beom Kyung

AU - Kim, Seungup

AU - Park, Junyong

AU - Ahn, SangHoon

AU - Han, KwangHyub

AU - Kim, Gyoung Min

AU - Kim, ManDeuk

AU - Park, Sung Il

AU - Won, Jong Yun

AU - Lee, Do Yun

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background and Aim: This study aims to evaluate clinical outcomes of patients with hepatocellular carcinoma who underwent transarterial chemoembolization (TACE) using drug-eluting beads (DEB). Patients and Methods: This study retrospectively compared the clinical outcomes of 250 consecutive patients who underwent DEB-TACE (n = 106) or conventional TACE (cTACE) (n = 144) in a tertiary center between January 2010 and April 2014. The median age of the patients was 62 years and 81.6% were men. The primary endpoint was overall survival (OS). The time to progression (TTP), radiological response rate using modified response evaluation criteria in solid tumors criteria at 1 month after treatment, and complication rates within 1 month were also compared. Results: The most common etiology was hepatitis B virus infection. The median index tumor size was 2.8 cm, and 150 (60.0%) patients had Barcelona Clinic Liver Cancer stage B. Median TTP in the cTACE group was longer than in the DEB-TACE group (13.3 vs10.8 months; P = 0.023). However, DEB-TACE and cTACE groups showed no significant differences for mean OS (46.6 vs 44.9 months; P = 0.660) and disease control rate at 1 month (78.3% vs 86.8%; P = 0.076). The OS, TTP, and disease control rate were also not different between two groups, even when subgrouped by index tumor size. The complication rates within 1 month were higher in the cTACE group (6.6% vs 14.6%; P = 0.048). Conclusions: Drug-eluting beads TACE appears to be a safe intra-arterial therapy. However, it is not superior to cTACE in terms of efficacy. Tumor size might not be a criterion to select treatment modality between cTACE and DEB-TACE in terms of efficacy.

AB - Background and Aim: This study aims to evaluate clinical outcomes of patients with hepatocellular carcinoma who underwent transarterial chemoembolization (TACE) using drug-eluting beads (DEB). Patients and Methods: This study retrospectively compared the clinical outcomes of 250 consecutive patients who underwent DEB-TACE (n = 106) or conventional TACE (cTACE) (n = 144) in a tertiary center between January 2010 and April 2014. The median age of the patients was 62 years and 81.6% were men. The primary endpoint was overall survival (OS). The time to progression (TTP), radiological response rate using modified response evaluation criteria in solid tumors criteria at 1 month after treatment, and complication rates within 1 month were also compared. Results: The most common etiology was hepatitis B virus infection. The median index tumor size was 2.8 cm, and 150 (60.0%) patients had Barcelona Clinic Liver Cancer stage B. Median TTP in the cTACE group was longer than in the DEB-TACE group (13.3 vs10.8 months; P = 0.023). However, DEB-TACE and cTACE groups showed no significant differences for mean OS (46.6 vs 44.9 months; P = 0.660) and disease control rate at 1 month (78.3% vs 86.8%; P = 0.076). The OS, TTP, and disease control rate were also not different between two groups, even when subgrouped by index tumor size. The complication rates within 1 month were higher in the cTACE group (6.6% vs 14.6%; P = 0.048). Conclusions: Drug-eluting beads TACE appears to be a safe intra-arterial therapy. However, it is not superior to cTACE in terms of efficacy. Tumor size might not be a criterion to select treatment modality between cTACE and DEB-TACE in terms of efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85013298037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013298037&partnerID=8YFLogxK

U2 - 10.1111/jgh.13501

DO - 10.1111/jgh.13501

M3 - Article

C2 - 27503585

AN - SCOPUS:85013298037

VL - 32

SP - 487

EP - 496

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 2

ER -